New peanut allergy treatment now in clinical trials

May 23, 2017, Monash University
New peanut allergy treatment now in clinical trials
L-R: Dr Sara Prickett, Professor Robyn O’Hehir and Emeritus Professor Jenny Rolland have worked together for years on the peanut allergy research and are co-founders of Aravax P/L. Credit: Monash University

A new peanut allergy treatment developed by Monash researchers is now beginning clinical trials in Melbourne and Adelaide.

Professor Robyn O'Hehir is Professor/Director of the Department of Allergy, Immunology and Respiratory Medicine at Alfred Health and Monash University. Her research team, co-led by Professor Jennifer Rolland, identified the critical components of the allergy therapy now being developed by Aravax, an Australian spinout biotechnology company.

The technology uses carefully selected fragments of peanut proteins to switch off . The product is designed to be safer, more rapid, and more convenient than other approaches currently under development. The Aravax team anticipates that simple, monthly injections will be sufficient to achieve clinical benefit.

Dr Pascal Hickey, CEO of Aravax, said the team wants to help people around the world who suffer from peanut allergy to live stress-free lives without constantly fearing a major health event from accidental consumption.

"Our technology aims to alleviate that stress by reprogramming the immune system to tolerate peanuts. By creating a safe, convenient and fast solution to a very serious problem we believe our product will have a global health impact by transforming the lives of patients and their carers," Dr Hickey said.

Almost two in every hundred Australians suffer from peanut allergy, and currently there is no therapy to reduce the severity of allergic reactions that can occur following accidental consumption. Despite patients attempting to follow a peanut-free diet, every year around 40 per cent of peanut allergic individuals will suffer a serious adverse event from inadvertent exposure, including anaphylaxis which can lead to death.

Traditionally, allergy specialists have treated patients using repeated doses of the -causing substance. Similar approaches are being explored to treat , but the use of preparations containing whole carries a high risk of severe reactions and requires daily dosing for lengthy periods. Aravax's product is different because it does not contain the parts of peanut protein that cause severe allergic reactions, and its once-a-month dosing regimen is a far simpler solution than remembering to take medication every day.

In the first ever trial of its product known as PVX108, Aravax will evaluate the safety and tolerability of single and repeated administration across a wide range of doses to determine an appropriate dosing regimen. This double-blinded and placebo controlled trial commenced dosing on 10 May 2017 with the first group of subjects safely receiving the lowest dose of PVX108. The trial is being conducted at CMAX Clinical Research in Adelaide, and at Nucleus Network in Melbourne.

Professor O'Hehir said the research has been supported by the Australian Food Allergy Foundation, the Alfred Hospital Trust, and the National Health and Medical Research Council.

"In 2015, we secured AUD $4.85M from the Medical Research Commercialisation Fund (MCRF) to develop the technology through to initial clinical . What is really exciting about this is not only the opportunity we have to get our therapeutic product up and running to protect the many sufferers, but that Australian is being funded in Australia for development to clinical trial," Professor O'Hehir said.

Explore further: Oral immunotherapy is safe, effective for peanut-allergic preschoolers, study suggests

More information: Peanut allergy sufferers interested in participating in the trials can contact Aravax for further information. www.aravax.com.au/product-development.html

Related Stories

Oral immunotherapy is safe, effective for peanut-allergic preschoolers, study suggests

August 10, 2016
Nearly 80 percent of peanut-allergic preschool children successfully incorporated peanut-containing foods into their diets after receiving peanut oral immunotherapy (OIT), a clinical trial has found. Peanut OIT involves eating ...

Anaphylaxis risk up for siblings of peanut allergic children

June 14, 2016
(HealthDay)—The risk of anaphylaxis is increased upon peanut introduction in siblings of children with peanut allergy, according to a study published online June 13 in Allergy.

Study suggests patch is safe, convenient mode of treatment for peanut allergy

October 26, 2016
A wearable patch that delivers small amounts of peanut protein through the skin shows promise for treating children and young adults with peanut allergy, with greater benefits for younger children, according to one-year results ...

Video: Why are people allergic to peanuts?

March 22, 2016
For 1 to 2 percent of the global population, eating a peanut butter and jelly sandwich could be potentially fatal. What makes peanut allergies so lethal, and why is the number of peanut-allergy sufferers on the rise?

Expert panel issues clinical guidelines to prevent peanut allergy

January 5, 2017
An expert panel sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, issued clinical guidelines today to aid health care providers in early introduction ...

Recommended for you

New genetic study could lead to better treatment of severe asthma

December 12, 2018
The largest-ever genetic study of people with moderate-to-severe asthma has revealed new insights into the underlying causes of the disease which could help improve its diagnosis and treatment.

Researchers discover unique immune cell likely drives chronic inflammation

December 11, 2018
For the first time, researchers have identified that an immune cell subset called gamma delta T cells that may be causing and/or perpetuating the systemic inflammation found in normal aging in the general geriatric population ...

Macrophage cells key to helping heart repair—and potentially regenerate, new study finds

December 11, 2018
Scientists at the Peter Munk Cardiac Centre have identified the type of cell key to helping the heart repair and potentially regenerate following a heart attack.

Study identifies a key cellular mechanism that triggers pneumonia in humans

December 11, 2018
The relationship between influenza and pneumonia has long been observed by health workers. Its genetic and cellular mechanisms have now been investigated in depth by scientists in a study involving volunteers and conducted ...

Immune cells sacrifice themselves to protect us from invading bacteria

December 11, 2018
Immune systems are working overtime as winter approaches. Stomach flu can turn the strongest individual into a bedridden convalescent. Viruses are spreading in kindergartens. This year's flu is approaching in full swing. ...

New light-based technology reveals how cells communicate in human disease

December 11, 2018
Scientists at the University of York have developed a new technique that uses light to understand how cells communicate in human disease.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.